Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagens.

Results of genetic toxicology tests are used by FDA's Center for Drug Evaluation and Research as a surrogate for carcinogenicity data during the drug development process. Mammalian in vitro assays have a high frequency of positive results which can impede or derail the drug development process. To reduce the risk of such delays, most pharmaceutical companies conduct early non-GLP (good laboratory practices) studies to eliminate drug candidate with mutagenic or clastogenic activity. Early screens include in silico structure activity assessments and various iterations of the ultimate regulatory mandated GLP studies.

[1]  R. Walmsley,et al.  An assessment of the utility of the yeast GreenScreen assay in pharmaceutical screening. , 2005, Mutagenesis.

[2]  J W Green,et al.  A review of the genotoxicity of marketed pharmaceuticals. , 2001, Mutation research.

[3]  N. Kruhlak,et al.  An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. , 2006, Regulatory toxicology and pharmacology : RTP.

[4]  William Pennie,et al.  Toxicogenomics in risk assessment: an overview of an HESI collaborative research program. , 2004, Environmental health perspectives.

[5]  Naomi L Kruhlak,et al.  Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. , 2007, Advanced drug delivery reviews.

[6]  David Kirkland,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo. , 2005, Mutation research.

[7]  Paola Gramatica,et al.  The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .

[8]  A. Bailey,et al.  The use of structure-activity relationship analysis in the food contact notification program. , 2005, Regulatory toxicology and pharmacology : RTP.

[9]  R. Tennant,et al.  Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. , 1991, Mutation research.

[10]  S Albertini,et al.  Comparative evaluation of the in vitro micronucleus test and the in vitro chromosome aberration test: industrial experience. , 1997, Mutation research.

[11]  N. Kruhlak,et al.  In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. , 2005, Regulatory toxicology and pharmacology : RTP.

[12]  N. Kruhlak,et al.  An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. , 2006, Regulatory toxicology and pharmacology : RTP.

[13]  N J Goddard,et al.  Development of a green fluorescent protein reporter for a yeast genotoxicity biosensor. , 1998, Biosensors & bioelectronics.

[14]  G M Pearl,et al.  Integration of computational analysis as a sentinel tool in toxicological assessments. , 2001, Current topics in medicinal chemistry.

[15]  V. Gervais,et al.  Assessment of the performance of the Ames II assay: a collaborative study with 19 coded compounds. , 2004, Mutation research.

[16]  Errol Zeiger,et al.  Measuring Intra-Assay Agreement for the Ames Salmonella Assay , 1991 .

[17]  Lutz Müller,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.

[18]  Richard M Walmsley,et al.  High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. , 2006, Mutation research.

[19]  E. Zeiger,et al.  Handbook of Carcinogenic Potency and Genotoxicity Databases , 1996 .